Letter From the Editor

As we approach the beginning of 2013, many promising advances are just over the horizon. In hepatology, a number of new drugs are being developed for […]

Letter From the Editor

When the direct-acting antiviral (DAA) agents boceprevir (Victrelis, Merck) and telaprevir (Incivek, Vertex) were first approved for the treatment of genotype 1 hepatitis C virus (HCV) […]

Letter From the Editor

Just as this issue was being prepared for publication, the US Food and Drug Administration approved a new drug, linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), for the […]

Letter From the Editor

Currently, patients with celiac disease must adhere to a strict gluten-free diet in order to avoid symptoms. In practical terms, this means foregoing many foods that […]

Letter From the Editor

Routine screening to prevent colorectal cancer has been a major focus of attention in recent years, in part because treatment of colorectal cancer is rarely successful […]

Letter From the Editor

While the advent of anti–tumor necrosis factor (anti-TNF) therapy has dramatically improved the treatment of inflammatory bowel disease (IBD), some clinicians remain concerned about the long-term […]

Letter From the Editor

Just as this issue of Gastroenterology & Hepatology was being prepared for publication, the Centers for Disease Control and Prevention announced a major change to their […]

Letter From the Editor

Hepatotoxicity is often a concern when prescribing certain drugs, as serious drug reactions can occur with potentially devastating consequences. While vigilance in this regard is warranted, […]

Letter From the Editor

In many ways, we live by numbers: Weather forecasts tell us what to wear, stock prices tell us how to invest, and digits on a clock […]

Letter From the Editor

Clostridium difficile infection is known to be associated with the use of antibiotics, and a recent announcement by the US Food and Drug Administration (FDA) highlights […]

Letter From the Editor

Drugs that target tumor necrosis factor (TNF) play a major role in the treatment of inflammatory bowel disease (IBD), but many questions about these drugs remain […]

Letter From the Editor

As we celebrate the beginning of 2012, everyone seems to be excited about making a fresh start. For many people, their New Year’s resolution is to […]

Letter from the Editor

For young physicians who are debating which career to pursue, clinical research is often an attractive option. Clinical studies are essential to medicine, and engaging in […]

Letter from the Editor

Recently, I saw a sign stating that only 1 in 4 people infected with hepatitis C virus (HCV) know that they are infected. This advertisement encouraged […]

Letter from the Editor

Given growing concerns about the cost of healthcare, physicians are increasingly having to consider 2 questions: Is this treatment effective? If so, is it cost-effective? While […]

Letter from the Editor

Inflammatory bowel disease (IBD) can cause a number of symptoms, but pain is sometimes one of the most troubling—not only is it common, but it can […]

Letter from the Editor

According to recent statistics published by the American Cancer Society (ACS), an estimated 102,900 new cases of colon cancer were diagnosed in 2010, resulting in an […]

Letter from the Editor

Last month, the United States Department of Agriculture (USDA) unveiled the federal government’s new food icon, MyPlate, a tool designed to help Americans make healthier food […]

Letter from the Editor

Just as this issue was being prepared for publication, the US Food and Drug Administration approved both boceprevir (Victrelis, Merck) and telaprevir (Incivek, Vertex), marking the start […]

Letter from the Editor

Last month, I discussed how medicine is always changing: how new information continues to alter our understanding of various conditions and their treatments. While ongoing developments […]